AI Threat Assessment · 26 May 2026

ZS Associates

Management Consulting
COOKED
7.4/ 10

“ZS Associates spent four decades building the gold standard in life sciences consulting — the kind of domain expertise that turns pharma executives into believers, the kind of proprietary datasets that make competitors weep, the kind of ZAIDYN platform integrations so deep that leaving would require an act of Congress. The tragic irony is that while they were busy becoming indispensable to an industry that moves at regulatory speed, Claude learned to do pharmaceutical market research, competitive intelligence, and commercial strategy in real-time — without the 15,000-person overhead or the six-figure project minimums.”

Business Model
8.0
Automation Risk
7.5
Moat Strength
5.5
Adaptability
6.5
Need Survival
7.5
AI Threat Level
BUSINESS MODEL REPLACEABILITY

Their value proposition was 'we own the domain expertise and the data that makes pharma decisions possible' — which worked beautifully until ChatGPT started analyzing drug trial data, Claude began writing market access strategies, and Perplexity started delivering real-time competitive intelligence faster than ZS could schedule the kickoff call. The consulting hours still bill; the reason to buy them by the thousands is evaporating.

8.0
WORKFORCE AUTOMATION RISK

Market research analysts, commercial strategists, and data visualization specialists are discovering that Claude can synthesize patient journey mapping, competitive positioning, and launch readiness assessments with the enthusiasm of a fresh MBA who never bills travel time and has actually read every clinical trial published since 2020.

7.5
MOAT STRENGTH

There is a genuine moat here: 40 years of proprietary life sciences data, ZAIDYN platform lock-ins, and Salesforce/Veeva integrations so deep that rip-and-replace would cost more than the consulting budget. The moat buys them time — it doesn't buy them immunity from an industry discovering that AI can answer the same strategic questions without the PowerPoint ceremony.

5.5
AI ADAPTABILITY SIGNALS

They launched 'agentic AI' for market research and got named an Everest Group Leader for 'operationalizing gen AI across commercial use cases' — which sounds impressive until you realize they're essentially charging premium rates to access the same foundation models their clients could license directly from OpenAI for 1/100th the cost.

6.5
WILL THE NEED SURVIVE AI?

Pharmaceutical strategy survives — pharma companies will always need to understand markets, optimize launches, and navigate regulatory complexity. Paying $2M for a six-month consulting engagement to get those answers doesn't, especially when Claude delivers equivalent insights in six hours, not six months.

7.5
Verdict

“ZS will survive as a premium brand for pharma executives who need someone to blame when the AI-generated strategy goes wrong, but the billable hours model dies the moment clients realize they're paying consultant rates for what amounts to very expensive prompt engineering. They built the perfect consulting mousetrap just as the mice learned to use ChatGPT.”

Scores are based on public information and AI analysis. This is an affectionate roast, not a financial assessment. The best companies use this as a mirror, not a verdict.

Roast another →